Anzeige
Mehr »
Login
Donnerstag, 03.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Warum Almonty Industries zum Schlüsselplayer für NATO-Staaten wird
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40BBS | ISIN: US2498454055 | Ticker-Symbol:
NASDAQ
02.04.25
21:50 Uhr
1,010 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
DERMATA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
DERMATA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur DERMATA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrDermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules347SAN DIEGO, CA / ACCESS Newswire / March 27, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of...
► Artikel lesen
DERMATA THERAPEUTICS Aktie jetzt für 0€ handeln
27.03.Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne2
27.03.Dermata Therapeutics, Inc.: BREAKING: Dermata's XYNGARI Phase 3 Trial Topline Data Meets All Primary Endpoints148- XYNGARI achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne - - XYNGARI is the first once-weekly...
► Artikel lesen
27.03.Dermata shares rise on positive acne treatment trial results1
25.03.Dermata Therapeutics, Inc. - 8-K, Current Report3
17.03.Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results223- Dermata expects to announce topline results from its XYNGARI Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 -- The Company recently entered into a Clinical...
► Artikel lesen
17.03.Dermata Therapeutics, Inc. - 8-K, Current Report2
17.03.Dermata Therapeutics, Inc. - 10-K, Annual Report4
04.03.Dermata Therapeutics, Inc.: Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI Phase 3 STAR-1 Clinical Trial for Acne74- STAR-1 topline results expected by the end of March 2025 - - Over 30 million acne patients seek treatment in the U.S. each year - - XYNGARI Phase 3 STAR-1 trial...
► Artikel lesen
25.02.Dermata Therapeutics: Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis561- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -- The Company recently entered into a Clinical Trial...
► Artikel lesen
29.01.Dermata Therapeutics: Dermata to Present on BioPub on January 31, 2025252- Dermata's Chief Executive Officer and Chief Development Officer will provide a corporate update and answer live questions from the biotech investment community -SAN DIEGO, CA / ACCESS Newswire / January...
► Artikel lesen
28.01.Dermata Therapeutics: Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment294- This is Dermata's first issued U.S. patent for XYNGARI, which uses its Spongilla technology to topically treat acne -- Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI clinical...
► Artikel lesen
23.01.Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules379SAN DIEGO, CA / ACCESS Newswire / January 23, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment...
► Artikel lesen
22.01.Dermata Therapeutics announces $2.55M private offering2
22.01.Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules312SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment...
► Artikel lesen
21.01.Dermata und Revance testen neue Behandlung gegen übermäßiges Schwitzen2
21.01.Dermata, Revance test new hyperhidrosis treatment3
21.01.Dermata Therapeutics: Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari with Daxxify749The Companies intend to first initiate a Phase 2a clinical trial evaluating Xyngari with Daxxify® to treat primary axillary hyperhidrosis -If successful, the Companies may explore clinical development...
► Artikel lesen
21.01.Dermata Therapeutics, Inc. - 8-K, Current Report1
16.12.24Dermata Therapeutics: Dermata Receives Approval from FDA for the Proprietary Name Xyngari326- Xyngari (formerly DMT310) is currently being studied in Phase 3 for the treatment of acne, with topline results from the first Phase 3 STAR-1 study expected in March 2025 - SAN DIEGO, CA / ACCESSWIRE...
► Artikel lesen
Seite:  Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1